We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

68 hedge funds and large institutions have $87.2M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 69 → 68 (-1)

39% less capital invested

Capital invested by funds: $144M → $87.2M (-$56.5M)

Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.17%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
11
Increased
23
Reduced
15
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$4.63M
2
TCM
Tang Capital Management
California
+$1.09M
3
BlackRock
BlackRock
New York
+$800K
4
BCM
Bridgeway Capital Management
Texas
+$634K
5
LCM
Lynx1 Capital Management
Puerto Rico
+$284K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.59M
2
PHS
PFM Health Sciences
California
-$1.54M
3
SCM
Sio Capital Management
New York
-$969K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$818K
5
IC
Ikarian Capital
Texas
-$687K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$237K +$10.9K +3,659 +3%
Charles Schwab
27
Charles Schwab
California
$165K -$345K -115,759 -57%
ACM
28
Altai Capital Management
California
$152K -$53.4K -17,903 -18%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$147K +$45.3K +15,203 +24%
Allspring Global Investments
30
Allspring Global Investments
North Carolina
$139K +$225K +75,519 New
IC
31
IEQ Capital
California
$105K +$169K +56,672 New
Morgan Stanley
32
Morgan Stanley
New York
$95K +$22.6K +7,576 +17%
Manulife (Manufacturers Life Insurance)
33
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$87.6K -$83.8K -28,093 -39%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$84K +$13.6K +4,564 +11%
Millennium Management
35
Millennium Management
New York
$75K -$119K -40,046 -50%
HM
36
Harvest Management
New York
$72K – – –
TD Asset Management
37
TD Asset Management
Ontario, Canada
$53K -$45K -15,105 -36%
UBS Group
38
UBS Group
Switzerland
$50K +$10.7K +3,576 +15%
JSC
39
Jackson Square Capital
California
$49K +$78.7K +26,396 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$43K +$895 +300 +1%
JP Morgan Chase
41
JP Morgan Chase
New York
$34K +$10.3K +3,463 +23%
AIG
42
American International Group
New York
$30K +$9.06K +3,038 +23%
CC
43
Cannell Capital
Wyoming
$30K +$36.3K +12,173 +307%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$25K +$4.28K +1,435 +12%
VF
45
Virtu Financial
New York
$25K +$39.9K +13,376 New
VOYA Investment Management
46
VOYA Investment Management
Georgia
$24.7K – – –
Invesco
47
Invesco
Georgia
$22K +$1.59K +532 +5%
Deutsche Bank
48
Deutsche Bank
Germany
$21K -$5.63K -1,889 -14%
SG Americas Securities
49
SG Americas Securities
New York
$20K +$31.7K +10,619 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$19K +$31.4K +10,535 New
1
2
3 4

PRDS Hedge Fund Activity: Q3 2022 in Review

68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2022, worth a combined $87.2M — down 39% from $144M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PRDS and 11 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 23 added.

The largest buyer was Goldman Sachs, adding an estimated $4.63M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.59M.

  • 68 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2022, down from 69 in Q2 2022.
  • Funds reported $87.2M of Pardes Biosciences, Inc. Common Stock stock for Q3 2022, down 39% quarter-over-quarter.
  • 11 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -1 holder.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q3 2022 was Goldman Sachs, an estimated $4.63M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2022 was T. Rowe Price Associates, an estimated $1.59M sold.

Based on aggregated 13F filings for Q3 2022.